You just read:

New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism

News provided by

Janssen Pharmaceuticals, Inc.

Mar 18, 2017, 08:13 ET